(Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth ...

InspireMD, in partnership with NAMSA, is set to initiate the pivotal, single-arm CGUARDIANS II study to assess the CGuard Prime 80cm carotid stent system’s usage in transcarotid artery ...

Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

Carotid artery disease, a progressive buildup of calcium deposits and cholesterol in the primary artery supplying blood to the brain, poses a risk of stroke but there are a few ways to treat it. Dr.

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid ...

InspireMD, Inc. has partnered with NAMSA to conduct the CGUARDIANS II pivotal study, evaluating the safety and effectiveness of the CGuard Prime carotid stent system in Transcarotid Artery ...

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a research note released on Monday. The firm issued a sell rating on the stock. Separately, Lake Street Capital started ...

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to ...